Direct-to-Consumer Genetic Testing Market Growth Size [2031]

Report Description

Direct-to-Consumer Genetic Testing Market Outlook 2031

The global direct-to-consumer genetic testing market size was USD 1.8 Billion in 2022 and is likely to reach USD 8.9 Billion by 2031, expanding at a CAGR of 24.3% during 2023–2031. The market growth is attributed to the high demand for customized DTC genetic tests.

Increasing demand for personalized DTC genetic tests is anticipated to boost the market during the forecast period. Genetic testing is performed on selected genes based on established guidelines for specific cancer types. However, expanded genetic testing (eGT) using large hereditary cancer gene panels has changed the landscape. eGT allows customization based on individual patient characteristics, such as cancer type, age of onset, and family history. Genetic testing is customized according to individual needs, which leads to improved risk assessment, personalized treatment, and improved outcomes.

• In July 2023, Quest Diagnostics Incorporated launched its first consumer-initiated genetic test. This test is exclusively available through the company’s consumer health business at questhealth.com. called Genetic Insights, which helps individuals understand their potential risk of developing certain inheritable health conditions with advanced technology and end-to-end support, including personalized health reports and access to genetic counseling.

Get Free Sample Report

The market report finds that the COVID-19 pandemic fueled the direct-to-consumer genetic testing market, owing to the increasing adoption of telehealth and telemedicine. The patient inclination toward online consultation services has increased during the pandemic. However, strict rules and social distancing norms were implemented to curb the spread of the virus, which encouraged consumers to adopt digital health alternatives to meet their medical and therapeutic needs.

Impact of Artificial Intelligence on Direct-to-Consumer Genetic Testing Market

Artificial intelligence (AI) is expected to fuel the DTC genetic testing market during the forecast period. DTC genetic testing allows consumers to directly access their genetic data without involving healthcare providers. AI algorithms analyze genetic information, which provides insights related to health, ancestry, wellness, and other traits. This empowerment encourages proactive health management.

Direct-to-Consumer Genetic Testing Market Dynamics

Get Free Sample Report

Major Drivers

Increasing prevalence of genetic disorders is expected to drive the direct-to-consumer (DTC) genetic testing market. Genetic testing plays a crucial role in screening, understanding the risk of developing certain diseases, and sometimes in medical treatment. Different types of genetic testing, such as predictive and presymptomatic testing, diagnostic testing, and carrier testing, are used in screening.

The incidence of genetic disorders, such as sickle cell disease, cystic fibrosis, Alzheimer's disease, and cancers, are increasing across the globe, which boosts the market, as DTC genetic tests provide detailed insights directly to consumers about their genetic information.

Existing Restraints

High cost of DTC genetic testing services is expected to hinder the market. Several manufacturers are focusing on product innovations and integrating next-generation technologies into their existing DTC tests. These high-end features contribute to the elevated pricing. The complexity of the test and the severity of the disease being assessed impact the cost. Some tests are comprehensive, which leads to increased prices for screening tests.

Emerging Opportunities

Increasing adoption of pharmacogenetics testing is expected to create lucrative opportunities for the market players. In DTC genetic testing, pharmacogenetic tests provide information about how an individual's body reacts to certain drugs based on their genetic makeup. These tests inform consumers of genetic variants that are related to how therapeutic drugs are metabolized in the body and have adverse reactions from certain therapeutic drugs. Furthermore, several companies are focusing on developing new products, thereby fueling the market.

• In February 2023, MyRx, a new UF Health service developed by pharmacists in the University of Florida College of Pharmacy, was launched to provide patients with a convenient way to understand their pharmacogenetics test results and improve drug discovery. Pharmacogenetic testing helps patients and clinicians understand why certain people do not respond to or have side effects from certain medications.

Scope of Direct-to-Consumer Genetic Testing Market Report

The market report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.

Direct-to-Consumer Genetic Testing Market Segment Insights

Test type Segment Analysis

Based on test type, the direct-to-consumer genetic testing market is divided into predictive testing, nutrigenomics testing, skincare testing, carrier testing, and others. The predictive testing segment is expected to expand at a significant pace during the projection period, owing to the increasing advancements and increase in the efficiency of genome analysis procedures.

Predictive genetic testing refers to the use of genomic information to predict an individual’s risk of developing a particular disease or condition. The segment growth is further attributed to the increasing adoption of personalized medicine and the rising incidence of genetic disorders.

The nutrigenomics testing segment is anticipated to hold a key share of the market in the coming years, as it is a specific genetic test that shows an individual's unique nutritional needs. The segment growth is further attributed to the rising awareness of nutrigenomics investigation that involves analyzing people's DNA to detect genetic variations, which further detects the risk of developing certain health conditions.

Get Free Sample Report

Technology Segment Analysis

In terms of technology, the global market is segregated into single nucleotide polymorphism chips, whole genome sequencing, targeted analysis, and others. The whole genome sequencing segment is projected to register a considerable CAGR during the forecast period, as it offers a comprehensive view of an individual’s entire genome, including all genes and non-coding genes.

The segment growth is further attributed to the increasing cancer-causing mutations. Whole genome sequencing (WGS) offers unique insight into pathogenesis and cancer biology with implications for prognosis, diagnostics, and therapy selection. It detects both sequence and structural variants that combine molecular genetics and cytogenetics.

The targeted analysis segment is anticipated to account for a major market share in the coming years. Specific genetic manufacturers are analyzed by using technologies, such as sequencing, polymerase chain reaction, and genotyping, in the targeted analysis. This allows for the identification of genomic variations that increase an individual’s risk of developing certain health conditions, such as cancer, cardiovascular disease, and inherited genomic disorders. This, in turn, is expected to increase the demand for the targeted analysis.

Get Free Sample Report

Distribution Channel Segment Analysis

On the basis of distribution channel, the direct-to-consumer genetic testing market is segmented into online platforms and over the counter. The online platforms segment is expected to register a robust growth rate during the forecast period. Direct to consumers genetic testing companies offer their services through online platforms that provide convenience to the consumer.

Online platforms allow customers to easily order a test kit and receive their results electronically. Online platforms further allow companies to innovate and offer new services and features, which helps consumers connect with others who share similar hereditary traits and interests.

The over the counter segment is projected to hold a large market share in the coming years, owing to the increasing over the counter products and the optimum availability of an extensive range of DTC consumer genetic testing. OTC medicines are purchased without a prescription from a healthcare professional. OTC medicines and tests are convenient, affordable, and relatively less complex.

Regional Analysis

In terms of region, the global direct-to-consumer genetic testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, owing to the increasing shift in the outlook of consumers towards genetic testing.

The regional market growth is further attributed to the increasing prevalence of chronic disorders and high demand for personalized geniting testing services. Furthermore, the presence of a large number of manufacturers in the US focuses on increasing the production of relatively low-cost units, which is expected to boost the market in the region.

The market in Europe is anticipated to expand at a rapid pace in the coming years, due to the increasing emphasis on early disease prevention and detection and the improved application of genomic examining among others. The regional market growth is further attributed to the increasing number of patients suffering from rare chronic illnesses and the consequently reduced quality of life.

• In February 2022, Invitae introduced the availability of LiquidPlex Dx and FusionPlex Dx in Europe, a part of industry-leading Anchored Multiplex PCR chemistry in-vitro diagnostic (CE-IVD) products. Invitae provides high-quality CE-IVD products to enable European pathologists and oncologists to efficiently provide vital information and to guide cancer therapy for patients.

Get Free Sample Report